<DOC>
	<DOCNO>NCT01132625</DOCNO>
	<brief_summary>This study characterize safety , tolerability , efficacy , pharmacokinetics , pharmacodynamics AUY922 adult patient advance solid malignancy Japan .</brief_summary>
	<brief_title>Dose Escalation Study AUY922 Advanced Solid Malignancies Japan</brief_title>
	<detailed_description />
	<criteria>Patients advance malignant solid tumor ECOG Performance Status ≤ 2 Patients must follow laboratory value : Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 109/L , Hemoglobin ( Hgb ) ≥ 8.5 g/dl , Platelets ( plt ) ≥ 100 x 109/L Potassium , Calcium , Magnesium , Phosphorus within normal limit correctable supplement AST/SGOT ALT/SGPT ≤ 2.5 x Upper Limit Normal ( ULN ) Serum bilirubin ≤ 1.5 x ULN , Serum albumin &gt; 2.5g/dl , Serum creatinine≤ 1.5 x ULN 24hour clearance ≥ 50 ml/min Able sign inform consent comply protocol Patients brain metastasis . Prior treatment HSP90 HDAC inhibitor compound . Treatment therapeutic dos coumarin anticoagulant . Pregnant lactating woman . Severe and/or uncontrolled acute chronic liver disease Severe and/or uncontrolled acute chronic renal disease Chronically significant heart disease History ( family history ) long QT syndrome . QTc ≥ 450 msec screen ECG , ischemic heart disease , heart fail , ECG abnormality , atrial fibrillation , atrial flutter ventricular arrhythmia include ventricular tachycardia Torsades de Pointes . Patients currently receive treatment medication relative risk prolong QTcF interval induce Torsades de Pointes Patients known disorder due deficiency bilirubin glucuronidation ( e.g Gilbert 's syndrome ) . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>HSP90</keyword>
	<keyword>molecular chaperone</keyword>
	<keyword>advanced solid tumor</keyword>
	<keyword>Japan</keyword>
</DOC>